Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

OBJECTIVE: Tumors harboring a POLE pathogenic variant, associated with high tumor mutational burden, are good candidates for immunotherapy. However, POLE pathogenic variants are not currently screened in routine clinical practice. Can these tumors be identified by means of an already available test?...

Descripción completa

Detalles Bibliográficos
Autores principales: Villy, M.-C., Masliah-Planchon, J., Melaabi, S., Trabelsi Grati, O., Girard, E., Bataillon, G., Vincent-Salomon, A., Le Gall, J., Golmard, L., Stoppa-Lyonnet, D., Bieche, I., Colas, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435919/
https://www.ncbi.nlm.nih.gov/pubmed/34541275
http://dx.doi.org/10.1016/j.gore.2021.100855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435919/
https://www.ncbi.nlm.nih.gov/pubmed/34541275
http://dx.doi.org/10.1016/j.gore.2021.100855

Ejemplares similares